Gilead Sciences’ Chief Scientific Officer John McHutchison to Leave the Company
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that John McHutchison, AO, MD, Chief Scientific Officer and Head of Research & Development, has decided to leave the company, effective next month. The company will immediately commence a search for his successor.
Dr. McHutchison joined Gilead in 2010 and under his leadership, Gilead has developed five medicines that have been used by more than 3.2 million people around the world for the curative treatment of chronic hepatitis C, and treatment of chronic hepatitis B. He also oversaw the company’s expansion into oncology with the development of Gilead’s first cancer medicine, Zydelig® (idelalisib). He was appointed Chief Scientific Officer in March 2018. During his tenure, he has been responsible for broadening and overseeing the company’s Research and Development pipeline, advancing candidates in new therapeutic areas, including oncology, cell therapy and inflammation.
“Over the past nine years, John’s scientific contributions and leadership have played an instrumental role in shaping our research efforts and in improving care for millions of patients with life-threatening illnesses,” said Daniel O’Day, Chairman and Chief Executive Officer of Gilead. “Under his guidance, the company was able to rapidly advance our hepatitis C portfolio, enabling therapies to reach people in need at an unprecedented pace, and he has continued to build on that work by helping the company expand its therapeutic areas of focus. We are grateful to John for his many contributions and wish him the best.”
“It has been a privilege to work alongside many exceptionally talented scientists,” said Dr. McHutchison. “I am grateful for the opportunity to make a difference in the lives of people with serious illnesses and confident that Gilead will continue to advance important new medicines for generations of patients to come.”
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
Sung Lee, Investors
Amy Flood, Media
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CES Unveiled in Paris to Shine Spotlight on Artificial Intelligence26.8.2019 10:00:00 EEST | Press release
Consumer Technology Association (CTA)®: WHAT: The Consumer Technology Association (CTA)® today announced that CES Unveiled in Paris will focus on emerging technology and trends around artificial intelligence (AI). More than 1,000 expected attendees will be able to view the latest AI innovations, learn about the latest tech trends and network with industry leaders. An official CES 2020 preview, CES Unveiled returns to Paris for a seventh year on Tuesday, Oct. 22 at Palais Brongniart. Attendees will experience a full day of tech that will feature more than 80 companies of all sizes, influential media, senior level executives, and prominent industry influencers from France and across Europe. Attendees will discover how AI is shaping our world, from changing enterprises to affecting ethics and policy. Industry experts and thought leaders from all over Europe will share insights on AI, enterprise solutions, mobility, Internet of Things (IoT) infrastructure, autonomous vehicles, diversity an
Study Investigates the Utility of Masimo ORi™, Oxygen Reserve Index, to Reduce Hyperoxia in Critically Ill Patients26.8.2019 09:00:00 EEST | Press release
Masimo (NASDAQ: MASI) announced today that in a randomized controlled study involving 150 ICU patients recently published as a letter in Intensive Care Medicine, researchers investigated whether monitoring with Masimo ORi™ (Oxygen Reserve Index) could reduce the time critically ill patients spend with moderate hyperoxia, compared to monitoring with oxygen saturation (SpO2) alone.1 ORi is an index of oxygenation in the moderate hyperoxic region, defined as arterial partial pressure of oxygen, PaO2 , in the range of 100 to 200 mmHg). As an “index” with a scale between 0.0 and 1.0, ORi can be trended to notify clinicians of changes in a patient’s oxygen reserve. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190825005030/en/ Masimo Root® and Radical-7® with ORi™ (Photo: Business Wire) Dr. Sigismond Lasocki and colleagues at the Centre Hospitalier Universitaire of Angers, France (CHU Angers), sought to evaluate whether controlli
S BLOCK 1000 Pax Interstellar Quantitative Summit Convenes in Bangkok26.8.2019 08:24:00 EEST | Press release
On August 21st, "S BLOCK Interstellar Quantitative Summit" officially convened in Bangkok, Thailand! This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190825005035/en/ (PHOTO: S BLOCK) Interstellar Quantification Assists S BLOCK to be Further Technologized S BLOCK is a brand-new multi-currency, cross-chain technology wallet from Switzerland, which jointly issued by S BLOCK foundation, Cloud Capital, Top Line, DAF, Stanford Blockchain Research center, MIT Media Lab and Cambridge Financial Alternative Center. Since its launch on June 15, it has bring an generous revenue of 6-15% per month for its millions of users. Interstellar quantification is S BLOCK's biggest source of revenue. Interstellar quantification is to realize timely capital exchanges with the quantification team under the agreement of Interstellar loan contract, so as to enlarge the capital scale at the fastest speed and lock up trading opportunities addition, S Blo
Building The Data Economy Within The G726.8.2019 08:00:00 EEST | Press release
Under the French Presidency, the G7 summit in Biarritz brings together the heads of state and government of the largest economies. This summit comes three months after the digital technology ministers meeting of G7 countries in Paris where the need to strengthen international digital cooperation was a key focal point of the debates. Discussions are still ongoing to resolve the challenges of the data economy, and the free flow of data in a trusted environment. Several international initiatives in favor of data circulation took place in recent months. As part of the Digital Single Market, the European Commission announced a new regulation on the free flow of non-personal data. The United States initiated a federal plan for data strategy. At the G20, Japan proposed the Osaka Track initiative to standardize the international rules for data flow. According to Dawex, the leading data exchange technology company and operator of the largest data marketplace, the flow of data in the G7 countrie
Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration23.8.2019 23:01:00 EEST | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced the closing of the global research and development collaboration agreement signed on July 14, 2019. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190823005335/en/ This agreement has received clearance from the U.S. Federal Trade Commission under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and merger control approval from the Austrian Federal Competition Authority. Under the terms of the agreement, the closing of this transaction triggers an upfront license fee payment of $3.95 billion by Gilead to Galapagos. In addition, Gilead has made an equity investment in Galapagos of approximately $1.1 billion (or approximately €960 million) by subscribing for new shares at a price of €140.59 per share, including issuance premium. As a result, Gilead now owns 13,589,686 ordinary shares of Galapagos, representing approximately 2
32 Leading Global Fashion and Textile Companies Make Commitments on Climate, Biodiversity and Oceans23.8.2019 10:47:00 EEST | Press release
Ahead of the G7 meeting at Biarritz from August 24-26, French President Emmanuel Macron, accompanied by Economy and Finance Minister Bruno Le Maire, Minister of Labour Muriel Pénicaud, and Deputy Minister of Ecological and Solidary Transition Brune Poirson, has invited to the Elysée Palace representatives of the 32 fashion and textile companies who have launched the Fashion Pact by his side. In April 2019, ahead of the G7 meeting, Emmanuel Macron had given François-Henri Pinault, Chairman and Chief Executive Officer of Kering (Paris:KER), a mission to bring together the leading players in fashion and textile, with the aim of setting practical objectives for reducing the environmental impact of their industry. In a historic move, given the scale and importance of the coalition that has been created, 32 leading companies from the fashion and textile industry have given themselves a set of shared objectives in the form of a Fashion Pact. The coalition includes groups and brands in Luxury,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom